Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis

24 Aug 2022

Abstract excerpt

BACKGROUND: The monoclonal antibody ublituximab enhances antibody-dependent cellular cytolysis and produces B-cell depletion. Ublituximab is being evaluated for the treatment of relapsing multiple sclerosis. METHODS: In two identical, phase 3, double-blind, double-dummy trials (ULTIMATE I and II), participants with relapsing multiple sclerosis were randomly assigned in a 1:1 ratio to receive intravenous...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Monoclonal and Polyclonal Antibodies Research
Share to Multiple Sclerosis Research Studies
Share to Rheumatoid Arthritis Research and Therapies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36001711
DOI: 10.1056/nejmoa2201904

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ublituximab versus Teriflunomide in Relapsing Multiple SclerosisPMID 36001711Read ↗

Emerging small-molecule treatments for multiple sclerosis: focus on B cellsSemantic proximity Read ↗

A type II anti-CD20 monoclonal antibody efficiently depletes CNS B cells in a mouse model of multiple sclerosisSemantic proximity Read ↗

Cladribine: mechanisms and mysteries in multiple sclerosisSemantic proximity Read ↗

Effect of Cumulative Exposure to Ocrelizumab on Memory B‐Cell Repopulation Dynamics in Multiple SclerosisSemantic proximity Read ↗

Generate-Boost: study protocol for a prospective, multicenter, randomized controlled, double-blinded phase II trial to evaluate efficacy and safety of bortezomib in patients with severe autoimmune encephalitisSemantic proximity Read ↗

Ocrelizumab Impairs the Phenotype and Function of Memory CD8+ T Cells: A 1-Year Longitudinal Study in Patients With Multiple Sclerosis.Semantic proximity Read ↗

Safety and Immune Effects of Blocking CD40 Ligand in Multiple SclerosisSemantic proximity Read ↗

Real-world Safety and Efficacy of Dimethyl Fumarate in Relapse-Remitting Multiple Sclerosis Patients: A Regional Cohort Report of the Iranian PatientsSemantic proximity Read ↗

Neurologic outcomes in people with multiple sclerosis treated with immune checkpoint inhibitors for oncologic indicationsSemantic proximity Read ↗

Masitinib is an oral, brain penetrant inhibitor of microglial and mast cell activity with neuroprotective potential in progressive forms of multiple sclerosisSemantic proximity Read ↗

T cell vaccination benefits relapsing progressive multiple sclerosis patients: a randomized, double-blind clinical trial.Semantic proximity Read ↗

Immunotherapy of multiple sclerosis: where are we? Where should we go?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.